- Firm believes ACL's sales and EPS estimates will not be impacted due to discontinuation of two Phase III studies (C-02-60 A and B) that were assessing the safety and efficacy of anecortave acetate in reducing the risk of advanced dry age-related macular degeneration (AMD) patients from progressing to wet AMD.
- Firm says ambitious AMD trials were always viewed by us as a long shot with a low chance for success.
- Firm believes Alcon can sustain 8-10% sales and 12-15% EPS growth over the next five years through OUS expansion, aging demographics and increasing penetration.

Other headlines for [ACL]

• ACL Yesterday 06:00am
  Alcon Inc Wachovia Raised ACL to Outperform from Market Perform
  
• ACL 10/28/2008 12:19pm
  Alcon Inc Merrill Lynch Cuts ACL to Neutral from Buy, price target: $105.00- price target cut to $105 from $178
  
• ACL 10/24/2008 09:08am
  Alcon Inc Wachovia Cuts ACL to Market Perform from Outperform
  
• ACL 10/24/2008 06:39am
  Alcon Inc Merrill Lynch Cuts ACL to Neutral from Buy, price target: $105- price target cut to $105 from $178
  
• ACL 10/23/2008 06:05am
  Alcon Inc JPMorgan Cuts ACL to Neutral from Overweight
  

Healthcare sector headlines

• NCST Today 09:48am
  Nucryst Pharmaceuticals Corp Majority holder calls for special meeting of shareholders to consider a return of capital of $0.80/shr
  
• GNBT Today 09:30am
  Generex Biotechnology Announces Positive Results of Metformin Chewing Gum Trial- Results of this fully compliant ICH-GCP conducted study indicate that the MetControl Metformin chewing gum and traditional Metformin tablets more...
  
• Today 09:30am
  Fed sets overnight reverse repos, accepts $25B
  
• 4568.JP Today 09:28am
  Daiichi Sankyo Co Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology- Results from three studies of its investigational molecule, DU-176b, will more...
  
• GENZ Today 09:22am
  Genzyme Corp European Patent on cross-linked Gel Slurries has been revoked by EPO board of appeal- Announces that the opposition they filed against European Patent EP 0466300 B1 to Genzyme Corporation has been more...